Dr. Smaglo is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1400 Holcomb Blvd
FC10.2004
Houston, TX 77030Phone+1 713-745-8763- Is this information wrong?
Summary
- Clinical focus on the management of pancreatic and other gastrointestinal cancers.
Research focuses are on the development of clinical and translational studies of all phases in pancreatic cancer.
Education & Training
Rice University Jones School of BusinessGraduate Certificate, Healthcare Management, 2018 - 2019
MedStar Health/Georgetown University HospitalFellowship, Hematology and Medical Oncology, 2010 - 2013
SUNY Health Science Center at BrooklynChief Residency, Internal Medicine, 2009 - 2010- SUNY Health Science Center at BrooklynResidency, Internal Medicine, 2006 - 2009
State University of New York Downstate Medical Center College of MedicineClass of 2006- Vassar CollegeAB, Biochemistry, Departmental Honors, 1998 - 2002
Certifications & Licensure
FL State Medical License 2021 - Present
TN State Medical License 2022 - 2026
TX State Medical License 2016 - 2025
WA State Medical License 2022 - 2025
AZ State Medical License 2022 - 2024
OK State Medical License 2020 - 2024
MS State Medical License 2022 - 2024- American Board of Internal Medicine Medical Oncology
- Join now to see all
Awards, Honors, & Recognition
- Oncology Faculty Educator of the Year Baylor College of Medicine Graduating Fellows, 2017
- Teacher of the Year Georgetown University Hospital Graduating Fellows, 2016
- Fellow American College of Physicians, 2016
- Join now to see all
Clinical Trials
- TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer Start of enrollment: 2018 Jan 18
- Postoperative Chemoradiation or Chemotherapy After Preoperative Chemotherapy for Gastric Cancers Start of enrollment: 2018 Jun 22
Publications & Presentations
PubMed
- LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from ...Benjamin L Musher, Eric K Rowinsky, Brandon G Smaglo, Wasif Abidi, Mohamed Othman, Kalpesh Patel, Salmaan Jawaid, James Jing, Amanda Brisco, Ann M Leen, Mengfen Wu, Li...> ;The Lancet. Oncology. 2024 Apr 1
- Trends Over Time in Recurrence Patterns and Survival Outcomes after Neoadjuvant Therapy and Surgery for Pancreatic Cancer.Laura R Prakash, Samuel H Cass, Ching-Wei D Tzeng, Jessica Maxwell, Rebecca A Snyder, Michael P Kim, Ryan W Huey, Brandon G Smaglo, Shubham Pant, Eugene J Koay, Robert...> ;Annals of Surgery. 2024 Mar 20
- Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma.Yousef, A., Yousef, M., Chowdhury, S., Abdilleh, K., Knafl, M., Edelkamp, P., Alfaro-Munoz, K., Chacko, R., Peterson, J., Smaglo, B., Wolff, R., Pant, S., Lee, M., Wil...> ;NPJ Precision Oncology. 2024 Feb 3
- Join now to see all
Lectures
- Targeting pancreatic cancer using nonengineered, multiantigen specific T cells (TACTOPS)AACR Immune Cell Therapies for Cancer meeting, San Francisco, CA - 7/20/2019
- Neoadjuvant Chemotherapy Alone Versus Neoadjuvant Chemoradiation Therapy for Locally Advanced Esophageal Cancer -AND- Who Benefits from Adjuvant Therapy following Neoa...Current Medical and Surgical Management of Esophageal Diseases Meeting
- State-of-the-Art Medical Management of Colorectal CancerBaylor St Luke’s Medical Center Oncology Grand Rounds, - 3/20/2017
- Join now to see all
Press Mentions
Pancreatic Cancer Treatment at MD Anderson Gave Me HopeNovember 29th, 2022- Marker Therapeutics Reports Interim Results of Its MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual MeetingMay 29th, 2020
Low-Dose Fish Oil No Help in Cutting Adenoma RiskNovember 21st, 2019- Join now to see all
Committees
- Cancer Liaison Physician, Committee on Cancer, Baylor St Luke's Medical Center 2017 - Present
- Member representing Dan L Duncan Comprehensive Cancer Center, Faculty Inclusion Ambassador 2016 - Present
- Co-Moderator, Neuroendocrine tumor board 2016 - Present
- Member, Adult Working Group of Protocol Review and Monitoring Committee 2016 - Present
- member, IRB (Georgetown) 2014 - 2016
Professional Memberships
- Member
- Member
- Fellow
- Member
Hospital Affiliations
University of Texas M.D. Anderson Cancer CenterHouston, Texas
Industry Relationships
- Speaker's Bureau, Taiho Oncology2017 - Present
External Links
- linkedInhttps://www.linkedin.com/in/brandon-smaglo-md-facp-16144783/
- Baylor Biohttps://www.bcm.edu/people/view/brandon-smaglo-md-facp/94a32b1c-2c17-11e6-a974-005056b104be
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
